School of Medicine

P. Roy Vagelos was head of the Department of Biological Chemistry at the School of Medicine from 1966-1975.

They seek to recognize the contributions made by teaching faculty in training medical students to become outstanding physicians.

Being studied is a drug designed to reduce the severe pain that can last for years after a bout with the disorder.

Courtesy photoThe annual Siteman Cancer Center holiday card can be purchased at the Barnard Health and Cancer Information Center.

Two St. Louis organizations have teamed up to create the Hope Center for Neurological Disorders, a unique collaboration dedicated to basic science research on a broad spectrum of nervous system conditions. A reception to celebrate the new initiative will take place at 4 p.m. on Tuesday, Oct. 5 at the Center for Advanced Medicine.

Miniscule, carefully engineered particles can detect the very beginning stages of clogged arteries in animals, thanks in large part to research at the School of Medicine. With a new five-year, $7.3 million grant, WUSM researchers will begin to translate this breakthrough into clinical advances.

Clinical trials testing treatments for neurological disorders such as Parkinson’s disease and epilepsy soon will be conducted under one roof at the School of Medicine, adding critical mass to the neuroclinical research program and convenience for patients enrolled in clinical trials.

P. Roy Vagelos, M.D., will present a lecture titled “Evolution from Basic to Translational Research (Washington University to Merck)” at noon Monday, November 29, in Cori Auditorium at Washington University School of Medicine. Vagelos was chairman of the Department of Biological Chemistry (currently the Department of Biochemistry and Molecular Biophysics) at the School of Medicine […]

Scientists at Washington University have received a five-year, $4.7 million grant from the National Cancer Institute to explore new ways to produce, distribute and use radionuclides to detect cancers.

Pain management researchers at the School of Medicine are recruiting people who have had shingles to test the effectiveness of an investigational drug designed to reduce the severe pain that can last for months or years after a bout with the disorder.